Avalon initiates phase II trial of AVN944 in pancreatic cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

Avalon initiates phase II trial of AVN944 in pancreatic cancer

GERMANTOWN, Maryland—Avalon Pharmaceuticals, Inc. has initiated a phase II clinical trial of AVN944 in combination with gemcitabine (Gemzar) in patients with newly diagnosed pancreatic cancer. After a dose-escalation phase, approximately 110 to 120 patients will be enrolled in an efficacy and safety phase. AVN944 is an oral small molecule agent that inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme that is critical for cells to be able to synthesize guanosine triphosphate (GTP), a molecule required for DNA synthesis and cellular signaling.

Articles in this issue
Avoiding copay shock
Induction chemo increases survival in unresectable NSCLC
Superselective chemo strategies for HCC
'Value meal dosing' of lapatinib is proposed
AMA approves CPT code for Axxent electronic brachytherapy
Zevalin/R after CHOP-R doubles CRs in follicular NHL
Active surveillance with delayed treatment appears to be a safe option for younger men with low-risk prostate cancer
RT plus local paclitaxel gel promising in esophageal ca
GeneSearch BLN Assay gets FDA approval for node assessment during surgery
TH vs TCH in metastatic breast cancer: 'Take your pick'
Sunitinib prolongs PFS in RCC: update
Diagnostic Dilemma: GI Disease
ACS studies link patients' insurance status to cancer outcomes
Novel MAGE-A3 immunotherapeutic promising as adjuvant therapy of early-stage non-small-cell lung ca
US consumers are shielded from the cost of healthcare
Related Videos
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Related Content
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC

ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC

April 23rd 2024
Article

ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024
Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Identifying Indications for Neoadjuvant Therapy in Cholangiocarcinoma

Identifying Indications for Neoadjuvant Therapy in Cholangiocarcinoma

April 17th 2024
Article

The recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Diane M. Simeone, MD “Thrilled” To Be UCSD Moores Cancer Center Director

February 26th 2024
Podcast

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

Sacituzumab Tirumotecan Shows Early Efficacy in Gastric/GEJ Cancers

April 15th 2024
Article

Sacituzumab tirumotecan elicited responses prominently in the second- and third-line and beyond setting and in those with high TROP2 expression.

Rectal Cancer Surgical Outcomes Improved at Accredited Hospitals

Rectal Cancer Surgical Outcomes Improved at Accredited Hospitals

April 9th 2024
Article

In-hospital mortality and complication rates were lower at accredited hospitals vs those not accredited for patients undergoing rectal cancer surgery.